All In Biotech

Drug Trial Radar · NCT06986811

CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors

First-in-pediatrics, Open Label, Exploratory, Externally Controlled Clinical Trial to Evaluate Safety, Efficacy and Pharmacokinetics of 7-ethyl-10-hydroxy Camptothecin (SN-38) Formulated as a Biocompatible Polymeric Nanofiber Membrane (CEB-01) for Treatment, in Addition to Standard of Care, of Pediatric Patients From Birth to Less Than 18 Years of Age With a Locally Resectable Tumors in Comparison to Standard of Care

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

May 2029

Study completion May 2029

Sponsor

Lead sponsor
CEBIOTEXIndustry
Sponsor type
Industry
Collaborators
CEBIOTEX S.L.
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the abdominal cancer tumor, CEB-01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of abdominal tumors after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in pediatric patients with locally resectable abdominal tumors including Soft Tissue Sarcoma (STS), high-risk Neuroblastoma (NB), Wilms tumor (WT), germ cell tumors (GCT), extracranial malignant rhabdoid tumor (eMRT), synovial sarcoma (SS), desmoplastic small round cell tumor (DSRCT) and fibrolamellar hepatocellular carcinoma (FL-HCC)

Conditions

  • Locally Resectable Pediatrics Tumors

Interventions

  • Standard surgeryProcedure

    The location and size of the tumor determine the type of surgery.

  • CEB-01Drug

    It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs) (Safety)Time frame: Through study completion, average 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Sant Joan de Déu

    Esplugues de Llobregat, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.